The FDA has approved an investigational new drug application for the evaluation of VSJ-110, a cystic fibrosis transmembrane conductance regulator activator, for treating allergic conjunctivitis, according to a press release.
A phase 2 study will evaluate the anti-inflammatory effects of the CFTR activator, under development by Vanda Pharmaceuticals, in an ocular allergic challenge model and will investigate “the prosecretory effects using standard tear production assessments,” the release said.
“This is an exciting milestone in the course of our collaboration with University
Uncategorized